Propanc Biopharma, Inc. (PPCB) Cash Flow Statement
Where PPCB’s cash came from and went, FY2026
June 30, 2026 · U.S. dollars- Cash from operations
- −$5.7M
- Capital expenditures
- $4,935
- Free cash flow
- −$5.7M
- Returned to shareholders
- $932,246
- Change in cash
- $819,918 cash at year-end $832,006
Drawn to scale: where the cash came from and how it was used. Hover for values.
PPCB operating cash flow, capex and free cash flow
PPCB cash flow trends, FY2017–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$2.2MFY2017 | −$5.7MFY2026 | — | |
| Capital expenditures | $1FY2017 | $4,935FY2026 | +157.3%/yr | |
| Free cash flow | −$2.2MFY2017 | −$5.7MFY2026 | — | |
| Stock-based compensation | $1.7MFY2017 | $4.6MFY2025 | +13.4%/yr | |
| Dividends paid | $391,749FY2021 | $932,246FY2026 | +18.9%/yr | |
| Share buybacks (net) | $0FY2017 | $590,250FY2023 | — |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
PPCB cash flow by activity
PPCB net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
PPCB cash flow statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$18.9M | −$58.9M | −$1.8M | −$2.7M | −$2.7M | −$2.0M | −$4.7M | −$5.8M | −$7.0M | −$7.9M |
| Depreciation & amortization | $22,703 | $20,187 | $21,656 | $22,931 | $5,671 | $1,993 | $2,473 | $2,306 | $2,225 | $2,166 |
| Stock-based compensation | — | $4.6M | $0 | $141,356 | $387,139 | $82,872 | $300,416 | $245,145 | $646 | $1.7M |
| Change in working capital | −$584,938 | $1.1M | $417,418 | $472,587 | $167,435 | $439,046 | $212,547 | $502,637 | $876,797 | $524,284 |
| Other non-cash items | $13.7M | $52.7M | $446,336 | $918,441 | $661,538 | $356,772 | $2.4M | $2.9M | $4.0M | $3.5M |
| Cash from operating activities | −$5.7M | −$405,168 | −$935,118 | −$1.1M | −$1.4M | −$1.1M | −$1.8M | −$2.1M | −$2.2M | −$2.2M |
| Investing activities | ||||||||||
| Capital expenditures | −$4,935 | −$2 | −$2 | −$1 | −$4 | −$4 | −$1 | −$2,873 | −$2.2M | −$1 |
| Investments (net) | — | — | — | — | — | — | $0 | −$2,874 | — | $0 |
| Acquisitions & other investing | $2 | — | — | — | — | — | — | $2,873 | $2.2M | −$2,873 |
| Cash from investing activities | −$4,933 | — | — | — | — | — | — | −$2,874 | −$2,874 | −$2,874 |
| Financing activities | ||||||||||
| Dividends paid | −$932,246 | — | −$192,960 | −$466,273 | −$700,340 | −$391,749 | — | — | — | — |
| Share repurchases & issuance (net) | — | — | — | −$590,250 | −$766,500 | −$776,044 | — | — | — | $464,286 |
| Net borrowing (repayment) | — | $755,412 | $918,837 | $590,250 | $766,500 | $282,000 | $1.5M | $1.1M | $2.4M | $1.6M |
| Shares issued | $0 | $0 | $23,057 | $24,711 | $99,285 | $0 | $450,000 | $1.1M | $0 | $0 |
| Other financing | $7.4M | −$264,656 | $192,960 | $1.6M | $2.1M | $1.9M | −$25,010 | −$78,820 | −$1,085 | $100,865 |
| Cash from financing activities | $6.5M | $490,756 | $941,894 | $1.1M | $1.5M | $1.1M | $1.9M | $2.1M | $2.4M | $2.2M |
| Summary | ||||||||||
| Net change in cash | $819,918 | −$8,997 | $11,038 | $5,980 | $1,812 | −$64,752 | $64,613 | −$17,527 | −$49,122 | −$52,027 |
| Cash at end of period | $832,006 | $12,088 | $21,085 | $10,047 | $4,067 | $2,255 | $67,007 | $2,394 | $19,921 | $69,043 |
| Free cash flow | −$5.7M | −$405,168 | −$935,118 | −$1.1M | −$1.4M | −$1.1M | −$1.8M | −$2.1M | −$2.2M | −$2.2M |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$4.6M | −$6.4M | −$3.1M | −$4.8M | −$4.1M | −$54.1M | −$430,183 | −$354,310 | −$358,578 | −$526,700 | −$584,384 | −$350,866 |
| Depreciation & amortization | $6,383 | $6,586 | $6,032 | $3,702 | $5,235 | $5,086 | $4,332 | $5,534 | $5,764 | $4,773 | $5,857 | $5,262 |
| Stock-based compensation | — | −$1.9M | — | — | — | $0 | — | — | — | — | — | — |
| Change in working capital | $103,217 | −$53,146 | $245,202 | −$907,686 | $640,965 | $167,781 | $260,527 | $68,939 | −$104,184 | $336,853 | $87,772 | $96,977 |
| Other non-cash items | $2.8M | $7.2M | $1.8M | $3.8M | $3.4M | $53.7M | $184,053 | $44,322 | $197,032 | $82,264 | $251,870 | −$84,830 |
| Cash from operating activities | −$1.7M | −$1.1M | −$1.0M | −$1.9M | −$27,186 | −$161,196 | $18,729 | −$235,515 | −$259,966 | −$102,810 | −$238,885 | −$333,457 |
| Investing activities | ||||||||||||
| Capital expenditures | −$51 | −$4,766 | −$2,275 | −$2,491 | −$3 | −$4 | −$5 | −$5 | −$4 | −$4 | −$1 | −$3 |
| Investments (net) | — | — | — | −$2,491 | — | — | — | $0 | — | — | — | — |
| Acquisitions & other investing | −$1 | $4,612 | −$1 | $2,491 | — | — | — | — | — | — | — | — |
| Cash from investing activities | −$52 | −$154 | −$2,276 | −$2,491 | — | — | — | — | — | — | — | — |
| Financing activities | ||||||||||||
| Dividends paid | — | — | −$932,246 | — | — | — | — | — | — | — | — | −$142,575 |
| Net borrowing (repayment) | — | −$18,386 | $0 | −$772,686 | $272,412 | $187,485 | $79,816 | $215,699 | $238,999 | — | — | — |
| Shares issued | $0 | $0 | $950,099 | $3.3M | $0 | $0 | $0 | $0 | $11,975 | $11,082 | $0 | $0 |
| Other financing | $2.1M | $1.0M | $953,598 | −$15,000 | −$264,656 | $25,000 | −$25,000 | $0 | $0 | $55,562 | $273,929 | $492,922 |
| Cash from financing activities | $2.1M | $981,614 | $971,451 | $2.5M | $7,756 | $212,485 | $54,816 | $215,699 | $250,974 | $66,644 | $273,929 | $350,347 |
| Summary | ||||||||||||
| Net change in cash | $388,304 | −$117,535 | −$41,500 | $590,649 | −$38,672 | $36,127 | $5,365 | −$11,817 | $14,863 | −$65,428 | $65,025 | −$3,422 |
| Cash at end of period | $832,006 | $443,702 | $561,237 | $602,737 | $12,088 | $50,760 | $14,633 | $9,268 | $21,085 | $6,222 | $71,650 | $6,625 |
| Free cash flow | −$1.7M | −$1.1M | −$1.0M | −$1.9M | −$27,186 | −$161,196 | $18,729 | −$235,520 | −$259,966 | −$102,810 | −$238,885 | −$333,460 |
| Free cash flow margin | — | — | — | — | −90.9% | — | — | — | — | — | — | — |
| Capex / revenue | — | — | — | — | 0.0% | — | — | — | — | — | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
PPCB cash generation
In fiscal 2026 (ended June 30, 2026), Propanc Biopharma generated -$5.7 million of cash from operations and spent $0.0 million on capital expenditures, leaving free cash flow of -$5.7 million. It returned $0.9 million to shareholders through dividends ($0.9 million) and net share buybacks ($0). Cash and equivalents rose by $0.8 million over the year.
Related: PPCB income statement, PPCB balance sheet. See the PPCB stock overview for the latest quote and news.
PPCB cash flow FAQ
What is Propanc Biopharma's free cash flow?
Propanc Biopharma's free cash flow was -$5.7 million in fiscal 2026: -$5.7 million of operating cash flow minus $0.0 million of capital expenditures It was -$0.4 million a year earlier..
How much cash does Propanc Biopharma generate from operations?
Propanc Biopharma generated -$5.7 million of cash from operating activities in fiscal 2026.
How much does Propanc Biopharma spend on capital expenditures?
Propanc Biopharma spent $0.0 million on capital expenditures in fiscal 2026, compared with $0.0 million the year before.
How much does Propanc Biopharma pay in dividends?
Propanc Biopharma paid $0.9 million in dividends in fiscal 2026.